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Background/aim: Familial Mediterranean fever (FMF) is a genetically recessive autoinflammatory disease caused by mutations in the
Mediterranean fever (MEFV) gene. The aim of this study was to investigate the frequencies of the most common MEFV mutations
among a sample of healthy individuals from the Havsa population of European Turkey, where FMF is less prevalent compared to Asian
Turkey.
Materials and methods: The study group consisted of 263 unrelated healthy adults. All of the participants were analyzed for the M694V,
V726A, M680I, and E148Q mutations in the MEFV gene.
Results: In total, 25 of the 263 individuals carried MEFV mutations (9.5%). The observed allele frequencies were 1.5% for M694V
(95% confidence interval [CI] 0.5-2.5), 2.6% for E148Q (95% CI 1.6-3.9), 0.5% for M680I (95% CI 0.0-1.1), and 0.0% for V726A. The
frequencies of the M694V, M680I, and E148Q mutations were not significantly different from allele frequencies (approximately 20%)
determined for other regions of Turkey where FMF is more prevalent.
Conclusion: These data suggest that the positivity of the MEFV gene mutation tests have lower predictive value in a population with
low FMF prevalence.
Key words: Familial Mediterranean fever, mutations, MEFV gene

1. Introduction
Familial Mediterranean fever (FMF) is a hereditary
autoinflammatory disease characterized by recurrent
episodes of fever, peritonitis, pleuritis, arthritis, and/or
erysipelas-like erythema. This condition is particularly
common in populations with Mediterranean ancestry,
including Arabs, Turks, Armenians, and Jews. Recently,
patients with FMF from varying ethnic backgrounds,
including Americans, Italians, and Japanese, with no
obvious connection to any high-risk population have been
reported. FMF is generally thought to be transmitted as an
autosomal recessive trait [1,2].
The Mediterranean fever (MEFV) gene is associated
with the pathophysiology of FMF and has been mapped
to chromosome 16 p13.3. It is comprised of 10 exons
and encodes a 781 amino acid protein called pyrin
or marenostrin, which is expressed in granulocytes,
monocytes, dendritic cells, and synovial, peritoneal, and

skin-derived fibroblasts [3,4]. Pyrin regulates inflammatory
response via activation of interleukin-1β (IL-1 β) and
NF-kappa в. MEFV mutations cause dysfunction of the
inflammasome complex, leading to excessive activation of
IL-1β [5].
To date, more than 70 MEFV gene mutations have been
reported. Five mutational alleles of MEFV, namely, M694V,
V726A, M694I, and M680I in exon 10 and E148Q in exon
2, account for 70%-80% of FMF cases in Mediterranean
countries [5]. Mutations in exon 10 are more prevalent
among FMF patients compared to non-FMF individuals,
whereas the variant E148Q is slightly more frequent in the
general population compared to FMF patients [2].
According to previous studies, the 4 most common
MEFV mutations among Turkish populations are M694V,
V726A, M680I, and E148Q [6,7]. In the present study, we
quantified the frequencies of these 4 MEFV alleles in healthy
individuals from the Havsa region, where the prevalence of
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FMF was previously reported to be approximately 0.006%
(95% CI 0.005-0.007) [8]. We compared our results with
the previously reported frequencies of these mutations in
different regions of Turkey where FMF is more prevalent.
2. Subjects and methods
We conducted this study in cohorts from the rural
Havsa region and a suburban Havsa town where we had
previously performed an epidemiological study [8]. Havsa
is a Turkish town on the border of Greece and Bulgaria.
A total of 263 healthy participants were recruited for
this study (139 women, mean age 44.7 ± 13.7 years; 124
men, mean age 43.5 ± 14.8 years; and a female/male ratio
1.12). None of the participants had symptoms or a family
history of FMF. The subjects were consecutively selected
from a pool of individuals accompanying other patients
visiting 2 local healthcare providers (health center no. 1
and no. 2, Havsa). The subjects were unrelated and had
lived for 3 generations in the same geographical location.
Informed consent was obtained for all study participants
in accordance with institutional guidelines.
To assess the carrier rate of the mutations, we screened
the subjects for the 4 FMF alleles M694V, V726A, M680I,
and E148Q. Venous blood samples were collected from the
subjects and preserved with ethylenediaminetetraacetic
acid (EDTA). Genomic DNA was isolated from the blood
samples using a Magna Pure LC High Pure PCR template
preparation kit (Roche Diagnostics, Mannheim, Germany),
and targeted PCR amplification of allelic regions, followed
by restriction fragment length polymorphism (RFLP)
analysis. The following specific primers were used: M694V:
forward,
5′-AGAATGGCTACTGGGTGGTGAT-3′;
reverse, 5′-AGAGAAAGAGCAGCTGGCGAATGTAT-3′.
M680I: forward, 5′-GAAACAAGTGGGAGAGG-3′;
reverse,
5′-CACCACCCAGTAGTAGCCATTCT-3′.
V726A: forward, 5′-AGAATGGCTACTGGGTGGTG-3′;
reverse, 5′-GCTGTGTTCTTCCCTCCATC-3′. E148Q:
forward, 5′- AAACGGCACAGATGATTCCGCAG-3′;
reverse, 5′-CCTTCTCTCTGCGTTTGCTCAGG -3′.
The restriction enzymes HinfI, HphI, AluI, and BstNI
were used for RFLP analysis of alleles M680I, M694V,
V726A, and E148Q, respectively (Roche Diagnostics,
Germany). All of these mutations were simultaneously
tested with appropriate positive and negative controls. The
positive results were repeated to ensure reproducibility.
The PCR products and the digested fragments were
electrophoresed on a 3% agarose gel and visualized by
ethidium bromide staining.
2.1. Statistical analysis
The allele frequencies were compared to values cited in the
literature for regions of Turkey with high FMF prevalence
rates using the χ²- test.

3. Results
Table shows the distribution of MEFV variations among
healthy populations from different regions of Turkey
including Havsa [9-13]. We analyzed the allele frequencies
and confidence intervals (CIs) for all the individuals.
The frequencies of the E148Q, M680I, M694V,
and V726A mutations in the Havsa cohort were 2.6%,
0.5%, 1.5%, and 0.0%, respectively. All variations were
heterozygous. One patient with FMF had been identified
in a previous field study [8]; in the present study, this
patient was found to be heterozygous for M694V. This
patient was not included among the 263 statistically
evaluated individuals.
4. Discussion
In this study, we investigated the frequencies of the 4 most
common variants of the MEFV gene, i.e. M694V, V726A,
M680I, and E148Q, observed in Turkish FMF patients
among healthy subjects from the Havsa region. We
previously reported that FMF prevalence in this part of the
country is rather low compared to other regions (0.006%)
(95% CI 0.005-0.007); the prevalence rates in other regions
of Turkey are in the range of 0.027%-0.25% [8].
The primary criterion for the recruitment of the study
cohort was to match the birthplace of the study individuals
with that of the individuals reported in the previous
study [8]. Our main aim was to investigate the mutation
carrier rate in a population where FMF is less prevalent.
We compared our frequency data to that reported in
previous studies including all necessary data concerning
the allelic and genotype frequencies of the 4 most common
mutations in Turkish FMF patients.
A series of several interesting studies regarding the
genetics of FMF in Turkey have been already published
[6,7,12,14,15]. In two of the largest studies, namely by the
Turkish FMF Study Group [6], and by Bilge et al. [7], the
most common MEFV alleles were M694V (51.4% and
44.5% respectively) followed by M680I (14.4% and 12.3%
respectively), V726A (8.6% and 9.2% respectively). Bilge
et al. refer to E148Q as the fourth most common MEFV
mutation (1%), while the Turkish FMF study group do not
provide any data.
In the present study, our results suggest that among
healthy individuals in Havsa, the difference between
frequencies of the 4 mutational alleles is not significant
(Table) when compared with the frequencies reported
in studies conducted for the regions where FMF is more
prevalent (χ²: 6.21, p: 0.28), [9-13]. In a study from
İstanbul, which has the most heterogeneous population
for MEFV mutations, a similar prevalence rate of M694V
was observed in 103 healthy individuals (1.5% CI: 0.000.31 for İstanbul vs. 0.5-2.5 for Havsa) [11]. The M680I
and E148Q allele frequencies were not significantly
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Table. Frequencies of MEFV alleles among healthy populations in different regions of Turkey.
Region

n

M694V

E148Q

M680I

V726A

Havsa (current study)

263

8/526 (1.5%)

14/526 (2.6%)

3/526 (0.5%)

0/526

χ² test

6.21

9.78

9.85

0.00

p value

0.31

0.13

0.08

Yigit9

100

8/200 (4%)

7/200 (3.5%)

5/200 (2.5%)

4/200 (2%)

Tunca10

49

3/98 (3%)

6/98 (6%)

0/98

2/98 (2%)

Cosan

103

3/206 (1.5%)

7/206 (3.4%)

1/206 (0.5%)

1/206 (0.5%)

Yilmaz12

100

3/200 (1.5%)

12/200 (6%)

5/200 (2.5%)

2/200 (1%)

Imirzalioglu¹³

66

4/124 (3.2%)

1/130 (0.08%)

2/128 (1.5%)

0/132

11

different from those found in the other studies (χ²: 9.85,
p: 0.08 and χ²: 9.78, p: 0.13, respectively). The V726A
mutation was not detected in the present study cohort, but
this allele was not found in one of the other regions and
statistical analysis could not be performed. Interestingly,
in our previous study, which was conducted in the same
region of Turkey, only 1 patient with FMF was identified,
and he was heterozygous for the M694V allele [8].
Although the E148Q mutation is one of the most
common mutations in patients with FMF, it occurs more
frequently in the general population compared to FMF
patients in the regions where the disease is prevalent. For
example, one study indicated that the allele frequency
was 3.5% among FMF patients vs. 6% in healthy Turkish
subjects [12]. Consistent with our study results, Cosan
et al. [11] reported that the E148Q mutation frequencies
were higher than those of other mutations in healthy
populations (2.6% [95% CI 1.6-3.9] and 3.4% [95% CI 0.95.9], respectively) (Table).
There are subtle and as yet, unexplained similarities
in FMF allele frequencies observed in other countries.
In Greece, frequencies of the common mutations mirror
the prevalence rates observed in Eastern Mediterranean
countries (M694V: 38.1%, M680I: 19.7%, V726A: 12.2%,
and E148Q: 10.9%). However, the E148Q allele frequency
among FMF patients in Greece is 10.9%, whereas it is
0% among the healthy population. Of note, the total
MEFV mutation carrier rate among healthy individuals
is relatively small (0.7%) in the healthy Greek population
[16].
Some researchers think that FMF and Behçet’s disease
(BD) have epidemiological similarities and have reported
that some MEFV mutations are more frequent in BD
patients compared to healthy controls [17,18]. As with
FMF, we demonstrated that the prevalence of BD in Havsa
was much lower (0.019%) compared to other regions of
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Turkey (2/10,000 in Havsa vs. 42/10,000, 11/10,000, and
37/10,000 in the prevalent regions) [8].
Despite the close association between HLA-B51
mutations and the pathogenesis of BD, the frequency
of HLA-B51 in the healthy population in regions where
BD is more prevalent is not significantly different
from populations where BD is less prevalent [8]. The
epidemiological similarities between these two diseases
could be because of environmental or other genetic factors.
In this region, although there are similarities in
the mutation frequencies, clinically diagnosed FMF
patients are very rare. As previously reported, the pyrin
gene penetrance displays different rates not only among
ethnically different populations but also among regional
groups of the same ethnicity [19]. More functional
studies are required to determine the degree to which
the aforementioned differences arise because of genetic
or population-specific factors. One of the limitations of
our study is the low statistical power for comparing the
frequency of MEFV variants in healthy populations from
different regions because of the low frequencies of some
variants.
In conclusion, we think that the positivity of MEFV
mutation tests have lower predictive value in a population
with low prevalence. A correlation between clinical
symptoms, MEFV mutations, and the geographical region
of patients should be considered in the diagnosis of FMF
patients.
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